GM 103 - GeneMedicine
Alternative Names: GM-103; GM-103 - GeneMedicineLatest Information Update: 28 Feb 2024
At a glance
- Originator GeneMedicine Co Ltd
 - Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
 - Mechanism of Action Angiogenesis inhibitors; Cell death stimulants; Immunologic cytotoxicity
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Phase I/II Solid tumours
 
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Liver-cancer in South Korea
 - 28 Feb 2024 No recent reports of development identified for preclinical development in Lung-cancer in South Korea
 - 20 Feb 2024 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Monotherapy) in South Korea (Intratumoural) (NCT06265025)